Related Experiment Video
Updated: Aug 5, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges
Pengxiao Su1, Ming Zhang1, Xin Kang1
1Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
Abstract:
At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and drug resistance. Therefore, c-Met targeting therapy may have great potential in urologic neoplasms. Many strategies targeting c-Met have been widely used in the study of urologic neoplasms. Although the use of targeting c-Met therapy has a strong biological basis for the treatment of urologic neoplasms, the results of current clinical trials have not yielded significant results. To promote the application of c-Met targeting drugs in the clinical treatment of urologic neoplasms, it is very important to study the detailed mechanism of c-Met in urologic neoplasms and innovate c-Met targeted drugs. This paper firstly discussed the value of c-Met targeted therapy in urologic neoplasms, then summarized the related research progress, and finally explored the potential targets related to the HGF/c-Met signaling pathway. It may provide a new concept for the treatment of middle and late urologic neoplasms.
Insights
Targeting the c-Met pathway shows promise for urologic neoplasms by inhibiting tumor growth and spread. Further research into c-Met mechanisms and novel drugs is crucial for clinical success.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), play a significant role in tumor progression.
- c-Met signaling is implicated in epithelial-mesenchymal transition (EMT), cell proliferation, angiogenesis, migration, invasion, and drug resistance in various cancers.
- In urologic neoplasms, c-Met is recognized for its involvement in tumor tissue EMT.
Purpose of the Study:
- To evaluate the therapeutic potential of c-Met targeting strategies in urologic neoplasms.
- To summarize the current research progress on c-Met in urologic neoplasms.
- To explore novel therapeutic targets within the HGF/c-Met signaling pathway for advanced urologic malignancies.
Main Methods:
- Literature review and analysis of existing studies on c-Met in urologic neoplasms.
- Discussion of the biological basis and clinical trial outcomes of c-Met targeted therapy.
- Exploration of potential molecular targets associated with the HGF/c-Met pathway.
Main Results:
- c-Met signaling, activated by HGF, promotes tumor cell mitosis, motility, angiogenesis, invasion, and drug resistance in urologic neoplasms.
- Despite a strong biological rationale, current clinical trials targeting c-Met in urologic neoplasms have not shown significant efficacy.
- Understanding the detailed mechanisms of c-Met in urologic neoplasms is essential for developing effective targeted drugs.
Conclusions:
- c-Met targeted therapy holds significant potential for treating urologic neoplasms, particularly in advanced stages.
- Innovation in c-Met targeted drug development and a deeper understanding of its mechanisms are necessary to improve clinical outcomes.
- Exploring novel targets within the HGF/c-Met pathway may offer new therapeutic avenues for middle and late-stage urologic cancers.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle